Cantor Fitzgerald Reiterates Neutral Rating for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE)‘s stock had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued on Monday,Benzinga reports. They presently have a $27.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 11.15% from the stock’s current price.

PFE has been the topic of several other reports. Guggenheim upped their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. CICC Research began coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Finally, Citigroup raised their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.59.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.29 on Monday. The stock has a market cap of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a 50 day moving average price of $25.63 and a 200-day moving average price of $26.23. Pfizer has a one year low of $23.11 and a one year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts expect that Pfizer will post 2.99 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PFE. Evolution Wealth Management Inc. raised its holdings in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Horizon Financial Services LLC grew its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new position in Pfizer during the 4th quarter valued at about $26,000. YANKCOM Partnership bought a new stake in shares of Pfizer in the 4th quarter valued at about $28,000. Finally, HFM Investment Advisors LLC raised its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.